 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| Rui Lisheng (romiplostim biosimilar) / Qilu Pharma
Trial completion, Trial completion date, Trial primary completion date: Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov) - Oct 18, 2024
P2/3, N=63, Completed, Sponsor: Qilu Pharmaceutical Co., Ltd.
Recruiting --> Completed | Trial completion date: Jul 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Feb 2024
- |||||||||| Rui Lisheng (romiplostim biosimilar) / Qilu Pharma
New P2/3 trial: QL0911-302: QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (clinicaltrials.gov) - Jun 13, 2024
P2/3, N=235, Not yet recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.
- ||| QL0911 (romiplostim biosimilar) / Qilu Pharma
Clinical, P3 data, Journal: Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial. (Pubmed Central) - Dec 22, 2023
P3
Recruiting --> Completed | Trial completion date: Jul 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Feb 2024 QL0911, a biosimilar to romiplostim (Nplate
- QL0911 (romiplostim biosimilar) / Qilu Pharma
EFFICACY AND SAFETY OF QL0911 IN ADULT PATIENTS WITH CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III TRIAL (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2001;
P3
QL0911 was well tolerated, and increased and maintained platelet counts in adults with ITP. QL0911, as a biosimilar of romiplostim (Nplate
- |||| Rui Lisheng (romiplostim biosimilar) / Qilu Pharma
New P2/3 trial: Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov) - May 8, 2023
P2/3, N=50, Completed, Sponsor: Qilu Pharmaceutical Co., Ltd.
- |||||||||| Rui Lisheng (romiplostim biosimilar) / Qilu Pharma
New P3 trial: QL0911-003: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov) - Nov 18, 2022
P3, N=216, Completed, Sponsor: Qilu Pharmaceutical Co., Ltd.
- |||||||| Rui Lisheng (romiplostim biosimilar) / Qilu Pharma
New P2/3 trial: Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov) - Sep 26, 2022
P2/3, N=60, Recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.